✨ Free AI Report
Aligos Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Aligos Therapeutics, Inc.
Company Research

Aligos Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Aligos Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for addressing unmet medical needs in viral and liver diseases. Founded with...

Analyst-debate audio for Aligos Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Aligos Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Company OverviewProduct PortfolioLeadership and Management TeamFinancial OverviewMarketing StrategiesMarket Overview and Competitors
Get Interactive Report Freeor start reading below
Live on AskCyborg
4/10Mixed
Aligos Therapeutics, Inc.

Aligos is a high-risk, catalyst-driven biotech whose value depends on clinical readouts for its hepatitis B and delta programs and on securing funding to reach them.

▶︎ Listen to the 90-second analyst debate
Competitors covered:Gilead Sciences, Inc.
4/ 10Mixed

Cyborg Score thesis

Aligos is a high-risk, catalyst-driven biotech whose value depends on clinical readouts for its hepatitis B and delta programs...

Read the full analyst-debate transcript →
Industry Infectious Disease Drugs
2 named competitors
1 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest Aligos Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Aligos Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for addressing unmet medical needs in viral and liver diseases. Founded with a mission to improve patient lives, Aligos leverages advanced science and technology to develop innovative treatments. The company is headquartered in South San Francisco, California, and has quickly risen to prominence in the biotech industry due to its robust research and development capabilities.

Company Overview

Pro stress-test →

Aligos Therapeutics, Inc. was established to tackle some of the most challenging diseases affecting global health, including chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH). The company focuses on creating a pipeline of therapeutic candidates that target these conditions, aiming to provide significant clinical benefits to patients. Aligos employs a multidisciplinary approach, combining expertise in medicinal chemistry, virology, liver disease biology, and clinical development.

Product Portfolio

Pro stress-test →

The product portfolio of Aligos Therapeutics, Inc. includes a range of therapeutic candidates targeting viral and liver diseases. The company’s lead programs are focused on developing treatments for CHB and NASH. Key products include:

  • ALG-010133: An antisense oligonucleotide (ASO) designed for the treatment of CHB.
  • ALG-000184: A small molecule capsid assembly modulator (CAM) for CHB.
  • ALG-055009: A thyroid hormone receptor-beta (THR-β) agonist for NASH.

Leadership and Management Team

Pro stress-test →

The leadership team at Aligos Therapeutics, Inc. comprises highly experienced professionals with deep expertise in the biotech and pharmaceutical industries. Key members include:

  • Dr. Lawrence Blatt: CEO and Chairman, with extensive experience in drug discovery and development.
  • Dr. Leonid Beigelman: President and Chief Operating Officer, with a strong background in virology and medicinal chemistry.
  • Dr. Matthew McClure: Chief Medical Officer, responsible for overseeing clinical development programs.

Financial Overview

Aligos Therapeutics, Inc. has demonstrated strong financial performance, supported by successful funding rounds and strategic partnerships. The company’s financial metrics reflect its growth trajectory and potential for future success. Key financial highlights include:

  • Revenue: Significant revenue growth driven by milestone payments and collaborations.
  • Funding: Over $100 million raised in initial public offerings (IPOs) and private placements.
  • Operational Efficiency: Effective management of operating expenses to maintain financial health.

Marketing Strategies

Aligos Therapeutics, Inc. employs strategic marketing approaches to enhance its visibility and reach within the biotech and pharmaceutical sectors. Key marketing strategies include:

  • Scientific Publications: Disseminating research findings through reputable scientific journals and conferences.
  • Partnerships and Collaborations: Engaging with leading pharmaceutical companies and research institutions.
  • Digital Presence: Leveraging online platforms and social media to connect with stakeholders and investors.

Market Overview and Competitors

The market for viral and liver disease treatments is highly competitive, with several established and emerging players. Key competitors of Aligos Therapeutics, Inc. include:

  • Gilead Sciences: A global leader in antiviral and liver disease therapies.
  • Intercept Pharmaceuticals: Known for its focus on NASH treatments.
  • Assembly Biosciences: Specializes in antiviral therapies.

Sales Strategies

Aligos Therapeutics, Inc. utilizes a multi-faceted sales strategy to ensure the successful commercialization of its therapeutic candidates. Key sales strategies include:

  • Direct Sales: Establishing direct sales channels to reach healthcare providers and institutions.
  • Partnerships: Collaborating with pharmaceutical companies for co-promotion and distribution.
  • Healthcare Engagement: Building relationships with key opinion leaders and healthcare professionals.

Technologies Utilized

Aligos Therapeutics, Inc. leverages cutting-edge technologies to drive its research and development efforts. Key technologies include:

  • Antisense Oligonucleotide (ASO) Technology: For targeted gene silencing in CHB treatment.
  • Small Molecule Development: Utilizing medicinal chemistry for novel therapeutic candidates.
  • Biological Assays: Advanced assays for evaluating drug efficacy and safety.

HR Practices

Aligos Therapeutics, Inc. prioritizes its employees’ well-being and professional growth through comprehensive HR practices. Key HR practices include:

  • Talent Development: Providing training and development opportunities for employees.
  • Inclusive Culture: Fostering a diverse and inclusive workplace environment.
  • Employee Benefits: Offering competitive compensation and benefits packages.

Corporate Responsibility

Aligos Therapeutics, Inc. is committed to corporate social responsibility (CSR) initiatives that positively impact society. Key CSR initiatives include:

  • Community Engagement: Supporting local communities through volunteerism and philanthropy.
  • Sustainability: Implementing environmentally sustainable practices in operations.
  • Patient Advocacy: Partnering with patient advocacy groups to support those affected by viral and liver diseases.

Future Plans

Looking ahead, Aligos Therapeutics, Inc. has ambitious plans to expand its therapeutic pipeline and advance its clinical programs. Key future strategies include:

  • Clinical Trials: Advancing current and new therapeutic candidates through clinical trials.
  • Global Expansion: Expanding operations and market presence internationally.
  • Innovation: Continuously investing in research and development to discover new treatments.

Our detailed report on Aligos Therapeutics, Inc. provides an in-depth analysis of the company’s strategies, financials, and market position. By subscribing to our service, you gain access to comprehensive insights that can inform your business decisions and investment strategies. Don’t miss out on this opportunity to stay ahead in the biopharmaceutical industry.


Get your detailed report on Aligos Therapeutics, Inc. by subscribing

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Aligos Therapeutics, Inc..

+1 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Aligos Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compare Aligos Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aligos Therapeutics, Inc. operates in Infectious Disease Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Infectious Disease Drugs research →
NEW · MCP server

Ask your AI assistant about Aligos Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aligos Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Aligos Therapeutics, Inc. do this quarter?”
“Is Aligos Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Aligos Therapeutics, Inc. do?+
Aligos Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for addressing unmet medical needs in viral and liver diseases. Founded with...
What is Aligos Therapeutics, Inc.'s Cyborg Score?+
Aligos Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aligos Therapeutics, Inc.'s main competitors?+
Named competitors include Gilead Sciences, Vir Biotechnology. The full competitive landscape is in the AskCyborg report.
How can I get the full Aligos Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aligos Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aligos Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Company Research

Gambling and Lotteries Industry BriefingStationery and Office Products Industry BriefingDefense Tech Industry BriefingAi Infrastructure Systems Industry BriefingPet Insurance Industry BriefingSelf-Storage Industry BriefingMetal Additive Manufacturing Industry BriefingAi Accelerator Hardware Systems Industry BriefingLuxury Wines & Spirits Industry BriefingEnzymatic Plastic Recycling Industry BriefingInfrastructure as a Service (IaaS) Industry Briefingluxury fashion apparel Industry Briefing

Explore Industry Research

Travel Insurance Industry Company Research ReportSecurity Services Industry Company Research ReportLandscaping and Grounds Maintenance Industry Company Research ReportJanitorial and Cleaning Services Industry Company Research ReportSustainability Consulting Industry Company Research ReportReal Estate Investment Trusts (REITs) Industry Company Research Report
Browse All Company ResearchBrowse All Industry ResearchRSS Feed